Venus Remedies rises on drug nod

Venus Remedies’ stock surged 10.5 per cent to close the day at Rs 188.65 on getting nod from the Drugs Controller General of India’s (DCGI) for a cancer drug.

Venus got approval to conduct Phase-1 clinical trials for its VRP 1620 molecule for the past three years. The stock opened at Rs 167.5 and made an intra-day high of Rs 192 and a low of Rs 160.1.